Iovance Biotherapeutics (IOVA) Tops Q4 EPS by 1c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $73.69 million versus the consensus estimate of $77.33 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Hesai Group (HSAI) Tops Q1 EPS by 8c
• Select Water Solutions signs 12-year water deal in Northern Delaware Basin
• H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)